This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Perioperative Sivelstat Administration for Liver Resection (KMS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takehiro Okabayashi, Kochi University
ClinicalTrials.gov Identifier:
NCT00738348
First received: August 18, 2008
Last updated: June 6, 2012
Last verified: June 2012
  Purpose
It is reported that sivelstat improved and preserved the postoperative renal function in the orthopedic management. Moreover because sivelstat reduced the migration of neutrophil, it improved acute lung injury. During liver resection, Pringle maneuver, clamping the hepatoduodenal ligament, was performed. Pringle maneuver causes reperfusion injury of the liver. We have a hypothesis that sivelstat prevent the warm shock of reperfusion injury of the liver by Pringle maneuver.

Condition Intervention
Liver Diseases Drug: sivelstat Drug: glucose

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Effect of Perioperative Sivelstat Administration for Liver Resection

Further study details as provided by Takehiro Okabayashi, Kochi University:

Primary Outcome Measures:
  • The incidence of liver damage due to reperfusion injury by Pringle maneuver was measured by several cytokines, including IL-8, IL-6, and HMGB-1. [ Time Frame: during hospitalization ]

Secondary Outcome Measures:
  • The duration of ICU stay and hospital stay, postoperative complications, and the liver damage at 6 POD, measuring hepato-biliary enzyme [ Time Frame: during hospitalization ]

Enrollment: 50
Study Start Date: April 2007
Study Completion Date: July 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 2
250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
Drug: sivelstat
sivelstat sodiumhydrate
Other Name: sivelstat sodiumhydrate, ONO PHARMACEUTICAL CO
Placebo Comparator: 1
250mL of 5% glucose was injected though the vein at 10mL per an hour
Drug: glucose
glucose

Detailed Description:
Whether the incidence of postoperative morbidities, such as liver failure, renal failure, or congestive heart failure, was reduced by administration of perioperative sivelstat.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • liver disease which surgical management was indicated

Exclusion Criteria:

  • weight loss greater than 10 per cent during the previous 6 months, signs of distant metastasis, or of respiratory, renal or heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00738348

Locations
Japan
Kochi Medical School
Kohasu-Okocho, Nankoku, Japan, 783-8505
Sponsors and Collaborators
Kochi University
Investigators
Study Director: Takehiro Okabayashi, MD, PhD Kochi Medical School
  More Information

Responsible Party: Takehiro Okabayashi, University, Kochi University
ClinicalTrials.gov Identifier: NCT00738348     History of Changes
Other Study ID Numbers: ESAR
Kochi University
Study First Received: August 18, 2008
Last Updated: June 6, 2012

Keywords provided by Takehiro Okabayashi, Kochi University:
surgery

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on June 22, 2017